Context-dependent rewiring of autocrine TGFβ/RhoA/ROCK1 under complete vs deprived serum conditions in TNBC transduced cells

Technical Summary: Context-Dependent Rewiring of Autocrine TGFβ/RhoA/ROCK1 in TNBC

Problem Statement
Triple-negative breast cancer (TNBC) remains a challenging malignancy characterized by high recurrence, early metastasis, and resistance to standard therapies due to the absence of estrogen, progesterone, and HER2 receptors. A critical factor in TNBC progression is the Transforming Growth Factor-beta (TGFβ) signaling pathway, which exhibits a dual role: suppressing tumors in early stages but promoting malignancy, epithelial-mesenchymal transition (EMT), and immunosuppression in late stages. While TGFβ's canonical SMAD-dependent pathways are well-studied, the mechanisms governing its non-canonical activation of the RhoA/ROCK1 axis in TNBC, particularly under varying nutrient conditions, are not fully understood. Furthermore, the specific contributions of the three TGFβ isoforms (TGFβ1, TGFβ2, and TGFβ3) to downstream RhoA/ROCK1 activation and cell survival in TNBC require clarification.

Methodology
The study utilized the MDA-MB-231 TNBC cell line to investigate the differential effects of TGFβ isoform depletion.

• Cell Transduction: Cells were transduced with lentiviral vectors harboring shRNA to knockdown specific TGFβ isoforms (shTGFβ1, shTGFβ2, shTGFβ3) or a non-targeting control (shNT). Stable clones were selected using puromycin.
• Culture Conditions: Experiments were conducted under two distinct conditions to assess context dependency:
  1. Complete Media (CM): Containing 10% Fetal Bovine Serum (FBS), providing baseline growth factors.
  2. Serum-Reduced (SR): Containing 2% FBS, designed to minimize exogenous growth factor interference.
• Assessments:
  • Gene Expression: RT-qPCR was used to verify knockdown efficiency and measure downstream expression of RhoA and ROCK1.
  • Cell Survival: Colony-forming assays were performed to evaluate clonogenic capacity and cell survival.
  • Clinical Correlation: KM Plotter data mining was employed to correlate RhoA and ROCK1 expression levels with disease-free survival in TNBC patients.

Key Results
The study revealed a context-dependent rewiring of the TGFβ/RhoA/ROCK1 axis, with significant differences observed between Complete Media (CM) and Serum-Reduced (SR) conditions.

• TGFβ1 Depletion:
  • CM Condition: Knockdown resulted in significant downregulation of RhoA and ROCK1, yet paradoxically enhanced cell clonogenic capacity compared to controls.
  • SR Condition: Knockdown led to downregulation of RhoA with unchanged ROCK1 levels, accompanied by a reduction in cell survival.
• TGFβ2 Depletion:
  • CM Condition: Depletion caused significant downregulation of both RhoA and ROCK1.
  • SR Condition: While RhoA expression remained unchanged, ROCK1 expression was elevated. Notably, TGFβ2 depletion in CM showed a significant elevation in colony formation, suggesting compensatory mechanisms.
• TGFβ3 Depletion:
  • Compensation Loop: Attempts to knockdown TGFβ3 resulted in an unexpected upregulation of TGFβ3 expression, likely due to a compensatory signaling loop.
  • CM Condition: RhoA expression was inconsistent, while ROCK1 was significantly downregulated.
  • SR Condition: Upon TGFβ3 recovery (due to compensation), both RhoA and ROCK1 expressions were significantly elevated.
• Clinical Correlation: KM Plotter analysis indicated that lower expression of RhoA and ROCK1 is associated with longer disease-free survival in TNBC patients (HR = 0.21 for RhoA), aligning with the observation that TGFβ1 depletion (which reduced RhoA/ROCK1) correlated with reduced survival in SR conditions.

Key Contributions

1. Context-Dependency: The study demonstrates that the regulatory relationship between TGFβ isoforms and the RhoA/ROCK1 axis is highly dependent on the presence of serum-derived growth factors. The SR condition provided a more stable and consistent readout for TGFβ-mediated effects, whereas CM conditions masked these effects through baseline growth inducers (e.g., IGF, FGF, EGF).
2. Isoform-Specific Rewiring: The research highlights that depleting individual TGFβ isoforms does not yield uniform downstream effects. Instead, it triggers distinct compensatory responses, such as the upregulation of ROCK1 upon TGFβ2 depletion in SR conditions or the recovery of TGFβ3 expression upon its own knockdown.
3. Non-Canonical Pathway Validation: The findings support the existence of a non-canonical TGFβ/RhoA/ROCK1 activation axis in TNBC, suggesting that RhoA and ROCK1 expression are dependent on specific TGFβ signaling inputs, particularly TGFβ1 and TGFβ2.

Significance and Claims
The authors claim that the serum-reduced (SR) condition approach offers a superior method for measuring TGFβ roles by minimizing interference from exogenous growth factors found in complete media. The study suggests that the TGFβ/RhoA/ROCK1 axis is a potential therapeutic target in TNBC, but with a critical caveat: targeting a single TGFβ isoform may induce ligand compensation or crosstalk with other pathways (such as PI3K/Akt or MAPK/ERK), potentially sustaining oncogenic modes.

The paper concludes that while the interaction between this non-canonical network and TNBC biology is complex, the observed dependence of RhoA/ROCK1 on TGFβ signaling warrants further investigation. The authors modestly state that extended assessments are necessary to fully validate these interactions and determine their clinical relevance as a new potential therapeutic strategy, emphasizing that single-isoform targeting may be insufficient due to compensatory mechanisms.